Aromatase inhibitors for breast cancer

Susanne Briest; Nancy E. Davidson

doi:10.1007/s11154-007-9039-z

Aromatase inhibitors for breast cancer

Susanne Briest, Nancy E. Davidson

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Endocrine therapy is a mainstay for the many women who develop in situ or invasive steroid receptor-positive breast cancer. The use of tamoxifen has reduced mortality in such women. Recently estrogen deprivation strategies have come under scrutiny. Here the use of aromatase inhibitors for treatment of postmenopausal endocrine-responsive breast cancer in the metastatic, adjuvant, and preoperative settings is reviewed.

Original language	English (US)
Pages (from-to)	215-228
Number of pages	14
Journal	Reviews in Endocrine and Metabolic Disorders
Volume	8
Issue number	3
DOIs	https://doi.org/10.1007/s11154-007-9039-z
State	Published - Sep 2007
Externally published	Yes

Keywords

Aromatase inhibitor
Breast cancer
Endocrine treatment
Estrogen receptor
Hormonal therapy
Postmenopausal

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1007/s11154-007-9039-z

Cite this

@article{29c75591a8cc49bc93c111ee16e5f144,

title = "Aromatase inhibitors for breast cancer",

abstract = "Endocrine therapy is a mainstay for the many women who develop in situ or invasive steroid receptor-positive breast cancer. The use of tamoxifen has reduced mortality in such women. Recently estrogen deprivation strategies have come under scrutiny. Here the use of aromatase inhibitors for treatment of postmenopausal endocrine-responsive breast cancer in the metastatic, adjuvant, and preoperative settings is reviewed.",

keywords = "Aromatase inhibitor, Breast cancer, Endocrine treatment, Estrogen receptor, Hormonal therapy, Postmenopausal",

author = "Susanne Briest and Davidson, {Nancy E.}",

year = "2007",

month = sep,

doi = "10.1007/s11154-007-9039-z",

language = "English (US)",

volume = "8",

pages = "215--228",

journal = "Reviews in Endocrine and Metabolic Disorders",

issn = "1389-9155",

publisher = "Springer Netherlands",

number = "3",

}

TY - JOUR

T1 - Aromatase inhibitors for breast cancer

AU - Briest, Susanne

AU - Davidson, Nancy E.

PY - 2007/9

Y1 - 2007/9

N2 - Endocrine therapy is a mainstay for the many women who develop in situ or invasive steroid receptor-positive breast cancer. The use of tamoxifen has reduced mortality in such women. Recently estrogen deprivation strategies have come under scrutiny. Here the use of aromatase inhibitors for treatment of postmenopausal endocrine-responsive breast cancer in the metastatic, adjuvant, and preoperative settings is reviewed.

AB - Endocrine therapy is a mainstay for the many women who develop in situ or invasive steroid receptor-positive breast cancer. The use of tamoxifen has reduced mortality in such women. Recently estrogen deprivation strategies have come under scrutiny. Here the use of aromatase inhibitors for treatment of postmenopausal endocrine-responsive breast cancer in the metastatic, adjuvant, and preoperative settings is reviewed.

KW - Aromatase inhibitor

KW - Breast cancer

KW - Endocrine treatment

KW - Estrogen receptor

KW - Hormonal therapy

KW - Postmenopausal

UR - http://www.scopus.com/inward/record.url?scp=34948839919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948839919&partnerID=8YFLogxK

U2 - 10.1007/s11154-007-9039-z

DO - 10.1007/s11154-007-9039-z

M3 - Review article

C2 - 17486453

AN - SCOPUS:34948839919

SN - 1389-9155

VL - 8

SP - 215

EP - 228

JO - Reviews in Endocrine and Metabolic Disorders

JF - Reviews in Endocrine and Metabolic Disorders

IS - 3

ER -

Aromatase inhibitors for breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this